Prostate Cancer
📧 Sign up to get email alerts when something new happens for Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-01-23FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) submitted by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2015-01-22Clinical Trial Update: Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate [Phase 2]
This Phase 2 trial evaluated a combination of estramustine, docetaxel, and zoledronate in men with hormone-refractory prostate cancer and ha…
-
CLINICAL_TRIALS trial_result · 2015-01-22Clinical Trial Update: Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluated oral estramustine and oral vinorelbine in patients with hormone-refractory prostate cancer. T…
-
CLINICAL_TRIALS trial_result · 2015-01-21Clinical Trial Update: Tetrathiomolybdate in Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating tetrathiomolybdate for hormone-refractory prostate cancer has completed. No efficacy or outcome details ar…
-
CLINICAL_TRIALS trial_result · 2015-01-21Clinical Trial Update: Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer [Phase 2]
A Phase 2 trial evaluating the combination of docetaxel and capecitabine in newly diagnosed localized or locally advanced prostate cancer ha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-01-21Clinical Trial Update: Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen [Phase 3]
This update notes the completion of a Phase 3 trial evaluating early access to cabazitaxel in metastatic hormone-refractory prostate cancer …
-
CLINICAL_TRIALS trial_result · 2015-01-21Clinical Trial Update: Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate [Phase 2]
A Phase 2 clinical trial testing estramustine, etoposide, and paclitaxel for hormonally responsive prostate cancer has completed.
-
CLINICAL_TRIALS research · 2015-01-21Clinical Trial Update: Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer [Phase 3]
This document outlines the safety monitoring protocol for a 200 mg dose of bicalutamide in patients with advanced prostate cancer in a Phase…
-
FDA approval · 2015-01-20FDA Approved: TRELSTAR — Supplemental Application (Verity Pharmaceuticals Inc.)
FDA approved a supplemental application for TRELSTAR (triptorelin pamoate) from Verity Pharmaceuticals Inc. The action expands the product's…
-
CLINICAL_TRIALS trial_result · 2015-01-19Clinical Trial Update: An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the efficacy and safety of Licroca Depot, a controlled-release product injected into the prostate, was…
-
CLINICAL_TRIALS trial_result · 2015-01-19Clinical Trial Update: Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer [Phase 2]
This trial update notes the completion of a Phase 2 study evaluating PTK787 for non-metastatic androgen-independent prostate cancer.
-
CLINICAL_TRIALS research · 2015-01-19Clinical Trial Update: Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer [Phase 2]
Phase 2 clinical trial update evaluating single-fraction real-time high-dose-rate brachytherapy for low- and intermediate-risk prostate canc…
-
CLINICAL_TRIALS withdrawal · 2015-01-19Clinical Trial Update: A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT [Phase 2]
A phase 2 clinical trial evaluating dovitinib in combination with androgen deprivation therapy for metastatic prostate cancer has been withd…
-
CLINICAL_TRIALS trial_result · 2015-01-19Clinical Trial Update: Cultured Circulating Tumor Cells in Prostate and Other Cancers
This document provides an update on a clinical trial investigating cultured circulating tumor cells in prostate cancer and other cancers.
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy [Phase 2]
Phase II trial investigating salvage radiation therapy with Taxotere for PSA failure after radical prostatectomy in prostate cancer; study t…
-
CLINICAL_TRIALS trial_result · 2015-01-15Clinical Trial Update: A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer [Phase 2]
A multicenter Phase II randomized trial comparing BIBF 1120 (nintedanib), BIBW 2992 (afatinib), and sequential administration of the two in …
-
CLINICAL_TRIALS trial_result · 2015-01-14Clinical Trial Update: Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
This completed clinical trial evaluated bone mineral loss in prostate cancer patients treated with a GnRH agonist alone versus GnRH agonist …
-
CLINICAL_TRIALS trial_result · 2015-01-13Clinical Trial Update: Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer [Phase 1]
Phase I trial of MT110 in multiple solid tumors has completed enrollment, evaluating MT110 in lung cancer (non-small cell and small cell), g…
-
CLINICAL_TRIALS research · 2015-01-09Clinical Trial Update: 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate [NA]
The clinical trial NCT00429338, sponsored by MD Anderson Cancer Center, evaluating 3T endorectal magnetic resonance spectroscopic imaging fo…
-
CLINICAL_TRIALS trial_result · 2015-01-09Clinical Trial Update: Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy [NA]
A clinical trial evaluating ultrasound elasticity and tissue strain-hardening imaging for prostate cancer patients undergoing radical prosta…
-
CLINICAL_TRIALS trial_result · 2015-01-08Clinical Trial Update: Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors [Phase 1]
Phase 1 study evaluating the combination of MGCD0103 and docetaxel in advanced cancers has been terminated.
-
CLINICAL_TRIALS trial_result · 2015-01-08Clinical Trial Update: Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.
Completed clinical trial evaluating immediate postoperative adjuvant hormonal therapy for high-risk localized or locally advanced prostate c…
-
CLINICAL_TRIALS trial_result · 2015-01-07Clinical Trial Update: IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen [Phase 2]
A Phase 2 trial evaluating abiraterone acetate's effect on PSA in men with prostate cancer completed and results were posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-01-07Clinical Trial Update: Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer [Phase 3]
A Phase 3 trial evaluating hormone therapy with radiation, with or without chemotherapy, in prostate cancer has completed and posted results…
-
CLINICAL_TRIALS trial_result · 2015-01-07Clinical Trial Update: Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer [Phase 1]
A Phase 1 dose-escalation study of cabazitaxel plus daily prednisolone in patients with hormone-refractory prostate cancer has completed.